FIELD: chemistry.
SUBSTANCE: invention relates to compounds of formula I and their pharmaceutically acceptable salts. The disclosed compounds have CDK1 and/or CDK2 kinase inhibiting activity. In formula 
R1 is selected from hydrogen, hydroxy-lower alkyl, C3-C6 cycloalkyl and R2-(X)n; X is selected from lower alkylene, hydroxy-lower alkylene, lower cycloalkylene or lower alkanoyloxy-lower alkylene; R2 is 
and 
is selected from phenyl and a 5- or 6-member heteroaromatic ring containing 1 or 2 heteroatoms selected from a group consisting of sulphur and nitrogen; R5 and R6 are independently selected from a group consisting of hydrogen, lower alkyl, halogen and lower alkoxy; and n equals 0 or 1.
EFFECT: design of a pharmaceutical composition for treating and preventing diseases whose condition can be improved by inhibiting CDK1 and/or CDK2 kinase, containing an effective amount of formula I compounds.
47 cl, 19 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THIAZOLINONE-2-SUBSTITUTED QUINOLINES | 2005 |
|
RU2395509C2 |
| QUINAZOLINYLMETHYLENETRIAZOLINONES AS CDK-1 INHIBITORS | 2005 |
|
RU2405782C2 |
| INFLUENZA VIRUS REPLICATION INHIBITORS, METHODS OF APPLICATION AND USING | 2016 |
|
RU2737190C2 |
| NOVEL 2,4-DIAMINOTHIAZOL-5-ONE DERIVATIVES | 2005 |
|
RU2395501C2 |
| 1, 5-NAPHTHYRIDINAZOLIDINONES EXHIBITING CDK1 ANTIPROLIFERATIVE ACTIVITY | 2005 |
|
RU2405781C2 |
| PYRROL[2,3-B]PYRAZINES AS SYK INHIBITORS | 2013 |
|
RU2656853C2 |
| COMPOUNDS OF PYRIDAZINAMIDE AND THEIR USE AS SYNTHETIC SYNECKINASIS INHIBITORS (SYK) | 2013 |
|
RU2627661C2 |
| PYROLLO [2,3-B]PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | 2012 |
|
RU2629999C2 |
| BRUTON'S TYROSINE KINASE INHIBITORS | 2013 |
|
RU2619465C2 |
| PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | 2006 |
|
RU2565071C2 |
